Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ramiro Guillen

Child & Adolescent Psychiatry Scottsdale, AZ Medical Doctor

NPI 1104993500 CMS profile 232123

11333 N Scottsdale Rd, Suite 280, Scottsdale, AZ 85254

Open in the dashboard

General payments

$30,810

255 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ramiro Guillen of Scottsdale, AZ is reported in the CMS Open Payments database as having received $30,810 across 255 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $205 6
2024 General $271 10
2023 General $439 15
2022 General $838 48
2021 General $3,530 50
2020 General $384 22
2019 General $25,143 104

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ramiro Guillen
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Ramiro Guillen were reported at $205. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Ramiro Guillen Child & Adolescent Psychiatry median Middle half National median
2019 $25,143 $129 $42–$419 $163
2020 $384 $81 $28–$226 $114
2021 $3,530 $115 $31–$326 $132
2022 $838 $124 $40–$382 $149
2023 $439 $130 $45–$420 $160
2024 $271 $141 $42–$490 $164
2025 $205 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $15,059 50 payments
  2. Ironshore Pharmaceuticals Inc. $9,793 34 payments
  3. Supernus Pharmaceuticals, Inc. $2,864 9 payments
  4. Sunovion Pharmaceuticals Inc. $685 54 payments
  5. Otsuka America Pharmaceutical, Inc. $519 25 payments
  6. Corium, Inc. $438 12 payments
  7. Alkermes, Inc. $321 14 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $316 20 payments
  9. AbbVie, Inc. $164 5 payments
  10. ITI, Inc. $140 7 payments
  11. Other $512 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $21,660 13 payments
  2. Food and Beverage $5,015 220 payments
  3. Travel and Lodging $4,122 21 payments
  4. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. SPRAVATO $14,840 41 payments
  2. Jornay PM 20mg capsules (Bottle of 100) $9,759 32 payments
  3. LATUDA $685 54 payments
  4. Azstarys $438 12 payments
  5. INVEGA SUSTENNA $360 18 payments
  6. INVEGA TRINZA $319 14 payments
  7. REXULTI $318 15 payments
  8. ARISTADA Cns $295 13 payments
  9. ARISTADA Cns $295 13 payments
  10. ABILIFY MAINTENA $270 13 payments
  11. Other $2,294 111 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

519

Median for Neuropsychiatry: 88

Drug cost

$11,486

Median for Neuropsychiatry: $2,689

Branded share of claims

31%

Median for Neuropsychiatry: 16.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lisdexamfetamine Dimesylate Generic 12 $2,266
Bupropion Xl Bupropion Hcl Brand 69 $1,511
Venlafaxine Hcl Er Venlafaxine Hcl Brand 45 $1,383
Atomoxetine Hcl Generic 12 $843
Lamotrigine Generic 31 $718
Fluoxetine Hcl Generic 20 $645
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 17 $567
Trazodone Hcl Generic 27 $527
Lorazepam Generic 36 $426
Escitalopram Oxalate Generic 31 $392

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $164
$164 — —
VIVITROL
  • Alkermes, Inc. $25
$25 — —
CAPLYTA
  • ITI, Inc. $21
$21 — —
Azstarys
  • Corium, Inc. $21
$21 — —
ZEPBOUND
  • Lilly USA, LLC $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

255 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record